<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04084990</url>
  </required_header>
  <id_info>
    <org_study_id>201908162</org_study_id>
    <nct_id>NCT04084990</nct_id>
  </id_info>
  <brief_title>Sleep Apnea and Fetal Growth Restriction</brief_title>
  <acronym>SAFER</acronym>
  <official_title>Sleep Apnea and Fetal Growth Restriction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ResMed Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Hebrew University Hadassah Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Rochester School of Medicine and Dentistry</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the association between obstructive sleep apnea (OSA) and fetal
      growth restriction (FGR) and to assess the role of auto-titrated positive airway pressure
      (aPAP) as antenatal therapy in these patients. Pregnant patients with diagnosed FGR will be
      screened for OSA first by screening questionnaire and then by home sleep monitor. Of those
      patients diagnosed with OSA, half will be assigned to use aPAP each night when sleeping and
      half will not (standard care).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fetal growth restriction (FGR) affects 5-10% of pregnancies and is one of the leading causes
      of perinatal morbidity and mortality.

      Obstructive sleep apnea (OSA) is a common disorder in which a person's breathing pauses or
      becomes shallow during sleep. These periods of low oxygen lead stress and inflammation which
      that may be harmful to both the mother and her fetus. OSA in pregnancy has been associated
      with poor maternal-fetal outcomes, including low birth weight, preterm delivery, FGR,
      gestational hypertension/preeclampsia, gestational diabetes and higher rates of neonatal ICU
      admission.

      Auto-titrated positive airway pressure (aPAP) is a machine that gently delivers pressurized
      air via a mask to keep a patient's airways free of obstruction during sleep. It is currently
      unclear whether treatment of OSA during pregnancy in women with known FGR can improve fetal
      and neonatal outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 18, 2019</start_date>
  <completion_date type="Anticipated">September 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective, parallel group, investigator-blinded, randomized controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Birth weight</measure>
    <time_frame>1 day</time_frame>
    <description>Weight of child at time of birth</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gestational age at delivery</measure>
    <time_frame>1 day</time_frame>
    <description>Gestational age at delivery</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">104</enrollment>
  <condition>Obstructive Sleep Apnea</condition>
  <condition>Fetal Growth Restriction</condition>
  <condition>Pregnancy Related</condition>
  <arm_group>
    <arm_group_label>aPAP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nightly use of aPAP when sleeping through the date of delivery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No aPAP</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No use of aPAP (standard of care)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>S9 VPAP Adapt</intervention_name>
    <description>Auto-titrated positive airway pressure</description>
    <arm_group_label>aPAP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 and ≤ 50

          -  Fetal growth restriction (defined as &lt;10th percentile based on routine second
             trimester ultrasound)

          -  Gestational age 22 to 28 completed weeks in the absence of 2 minor or 1 major markers
             of aneuploidy.

        Exclusion Criteria:

          -  Multiple gestation

          -  Other known cause of fetal growth restriction (including congenital anomalies or
             intrauterine infection)

          -  Preexisting diagnosis of OSA being treated with aPAP

          -  Chronic pulmonary disease (cystic fibrosis, moderate persistent asthma)

          -  Hemoglobinopathies (sickle cell anemia, thalassemia)

          -  Craniofacial anomalies
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ellen Lockhart, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University in Saint Louis</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ellen Lockhart, MD</last_name>
    <phone>314-454-8707</phone>
    <email>elockhart@wustl.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alexander Hincker, MD</last_name>
    <phone>314-362-2628</phone>
    <email>hinckera@wustl.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Washington University in St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ellen Lockhart, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Nardozza LM, Caetano AC, Zamarian AC, Mazzola JB, Silva CP, Marçal VM, Lobo TF, Peixoto AB, Araujo Júnior E. Fetal growth restriction: current knowledge. Arch Gynecol Obstet. 2017 May;295(5):1061-1077. doi: 10.1007/s00404-017-4341-9. Epub 2017 Mar 11. Review.</citation>
    <PMID>28285426</PMID>
  </reference>
  <reference>
    <citation>Lavie L. Oxidative stress in obstructive sleep apnea and intermittent hypoxia--revisited--the bad ugly and good: implications to the heart and brain. Sleep Med Rev. 2015 Apr;20:27-45. doi: 10.1016/j.smrv.2014.07.003. Epub 2014 Jul 24. Review.</citation>
    <PMID>25155182</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>September 7, 2019</study_first_submitted>
  <study_first_submitted_qc>September 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 11, 2019</study_first_posted>
  <last_update_submitted>July 1, 2020</last_update_submitted>
  <last_update_submitted_qc>July 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Washington University School of Medicine</investigator_affiliation>
    <investigator_full_name>Alexander M. Hincker</investigator_full_name>
    <investigator_title>Assistant Professor, Department of Anesthesiology</investigator_title>
  </responsible_party>
  <keyword>aPAP</keyword>
  <keyword>OSA</keyword>
  <keyword>FGR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
    <mesh_term>Fetal Growth Retardation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

